Henry Meds vs WePeptideRx
Two GLP-1 desks, one scoreboard. We put Henry Meds and WePeptideRx head-to-head on the published Brief Score — the same six factors, scored the same way.
Henry Meds
The verdict
Henry Meds takes this head-to-head.
Henry Meds scores 84 to 67 on our six-factor Brief Score — A flat-fee compounded pioneer — simple model, but its price has drifted to the higher end of our ranking.
That doesn't make WePeptideRx a bad call — it's best for readers who want premixed ready-to-inject glp-1 with microdose protocol options. Weigh the six factors below against your own priorities before you decide.
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.
Factor by factor
Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.
Price, coverage & the tracker
| Henry Meds | WePeptideRx | |
|---|---|---|
| Brief Score | 84/100 (B) | 67/100 (C) |
| Semaglutide | $249/mo | From $249/mo (compounded) |
| Tirzepatide | $349/mo | From $249/mo (compounded) |
| Coverage | Multi-state | Coverage not published |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Injection only |
| On the tracker | Risingprice rising | Newnew to the tracker, no prior reading |
Henry Meds: Flat-fee pioneer, but its line has drifted to the higher end of the tracker.
WePeptideRx: New to the tracker on 1 August 2026. The published line reads From $249/mo (compounded) at our first reading; there is no earlier reading of ours to compare it against yet.
● Not sold on either?
CoreAge Rx tops the whole ranking at 94/100.
The steadiest desk in the ranking: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.
Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.